Adial Pharmaceuticals (ADIL) Free Cash Flow (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Free Cash Flow of -$1.6 million for Q1 2026, up 68.8% sequentially from -$5.2 million in Q3 2025, and down 1.7% YoY from -$1.6 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Free Cash Flow (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Free Cash Flow for 10 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 1.7% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.5 million (up 7.31% YoY) and the FY2025 annual result came in at -$6.5 million, up 6.21% from the prior year.
- Free Cash Flow improved to -$1.6 million in Q1 2026 per ADIL's latest filing, from -$5.2 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $841248.0 in Q4 2022 and troughed at -$5.5 million in Q3 2024.
- A 5-year average of -$2.3 million and a median of -$1.9 million in 2023 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow jumped 135.45% in 2022, then slumped 1249.78% in 2024.
- Over 5 years, Free Cash Flow stood at $841248.0 in 2022, then slumped by 243.24% to -$1.2 million in 2023, then tumbled by 353.83% to -$5.5 million in 2024, then climbed by 5.49% to -$5.2 million in 2025, then soared by 68.8% to -$1.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$1.6 million, -$5.2 million, and -$1.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Adial Pharmaceuticals | 29.02 Mn | 29.02 Mn | - | -6.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.61 Mn |
| Mar 31, 2026 | -1.61 Mn |
| Sep 30, 2025 | -5.17 Mn |
| Sep 30, 2025 | -5.17 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.59 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Sep 30, 2024 | -5.47 Mn |
| Jun 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -2.15 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Mar 31, 2024 | -1.63 Mn |
| Dec 31, 2023 | -1.20 Mn |
| Dec 31, 2023 | -1.20 Mn |
| Sep 30, 2023 | -405,139.00 |
| Sep 30, 2023 | -405,139.00 |
| Jun 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | -1.89 Mn |